AMRX vs SPY
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus SPDR S&P 500 ETF Trust (SPY) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
SPDR S&P 500 ETF Trust (SPY) common stock listed on US.
Latest reported AMRX revenue for 2026-06-30 was $1.52B. Net income was $119.9M. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
SPY does not have a complete income-statement cache yet.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. SPY currently screens at market cap $0.
Not investment advice. Open the AMRX and SPY stock pages for the full models.
Not investment advice.